Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOptima Health Regulatory News (OPT)

Share Price Information for Optima Health (OPT)

Share Price is delayed by 15 minutes
Get Live Data
191.50    0.00 (0.00%)
Bid:
190.00
Ask:
193.00
Spread: 3.00 (1.579%)
Market Cap: £208.30m
OPT Live PriceLast checked at - London Stock Exchange

Intraday Optima Health Share Chart

Full Year Trading Update

17 Apr 2026 07:00

RNS Number : 9162A
Optima Health PLC
17 April 2026
 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as amended by regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310. Upon the publication of this announcement via Regulatory Information Service, this inside information is now considered to be in the public domain.

17 April 2026

Optima Health plc

("Optima", the "Company", and, together with its subsidiaries, the "Group")

Full Year Trading Update

Full year adjusted EBITDA expected to be c.10% ahead of market expectations

Optima Health (AIM: OPT), the UK's leading provider of technology enabled corporate health and wellbeing solutions, today announces an unaudited trading update for the year ended 31 March 2026.

Further to the previously communicated commentary on current trading announced on 31 March 2026, Optima now expects FY26 Adjusted EBITDA to be ahead of market expectations[1] by c.10%.

Optima has continued to make strong progress against its strategic objectives and medium-term targets of £200 million revenue and £40 million adjusted EBITDA. The recent acquisition of PAM, which completed on 26 March 2026, positions the enlarged Group to capitalise on the growing market opportunity, whilst benefiting from significant operational and cost synergies which will help Optima achieve its medium-term EBITDA target.

The previously disclosed procurement matter has now been settled. Other operating income of £2.3 million was recognised in H1 FY26, and a further £2.4 million has been recognised in H2 FY26.

A full trading update will be made later in Q2 2026.

Jonathan Thomas, Chief Executive Officer, said: "Optima's strong financial performance in H2, ahead of market expectations, reflects the consistent progress we have continued to make against our strategic objectives. The recent transformational acquisition of PAM has further solidified Optima's position in the attractive and growing occupational health market. We look forward to increasing our presence in our core markets, alongside seeking new opportunities, as we continue to accelerate growth."

 

Enquiries

Optima Health

Jonathan Thomas, CEO

Heidi Giles, CFO

 

+44(0)3300085113

media@OptimaHealth.co.uk

Panmure Liberum Limited

Nominated Adviser and Corporate Broker

Emma Earl / Will Goode/ Mark Rogers

Rupert Dearden

 

+44 (0)20 3100 2000

 

Cavendish Capital Markets

Joint Broker

Geoff Nash/Ben Jeynes/George Lawson

Julian Morse/Michael Johnson/Nigel Birks

 

+ 44 (0)20 7220 0500

ICR Healthcare

UK Financial PR Adviser

Mary-Jane Elliott / Angela Gray / Lindsey Neville

optimahealth@icrinc.com

 

 

About Optima Health

Optima Health is the UK's leading provider of occupational health and wellbeing services, delivering clinically led, technology-driven solutions to organisations across the public and private sectors. With a team of more than 2,000 including 1,250 clinicians, Optima Health supports millions of employees and operates from a network of more than 50 clinics nationwide.

 In addition to its core UK market, Optima Health also operates in Ireland under Optima Health Ireland, providing occupational health services to clients nationwide.

 

For more information visit www.optimahealth.co.uk

 


[1] FY26 adjusted EBITDA market consensus £18.1 million

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTUBVVRNRUSARR
Date   Source Headline
9th Jul 20256:02 pmRNSHolding(s) in Company
8th Jul 20257:00 amRNSFull Year Results
2nd Jul 202512:49 pmRNSHolding(s) in Company
30th Jun 20251:47 pmRNSHolding(s) in Company
5th Jun 20257:00 amRNSNotice of Full Year Results
3rd Jun 20252:37 pmRNSHolding(s) in Company
12th May 20257:00 amRNSFull Year Trading Update
6th May 20257:00 amRNSOptima Health to acquire Care first
11th Apr 20257:00 amRNSOptima Health to acquire Cognate Health Limited
10th Apr 20256:06 pmRNSHolding(s) in Company
24th Mar 20257:00 amRNSHolding(s) in Company
21st Mar 20259:29 amRNSDirector / PDMR Shareholding
10th Mar 20252:27 pmRNSHolding(s) in Company
3rd Mar 20252:11 pmRNSHolding(s) in Company
11th Feb 20257:00 amRNSOptima Health Secures First DART License with NHS
6th Feb 20254:17 pmRNSOptima to deliver services to UK Armed Forces
20th Jan 20257:06 amRNSDirector / PDMR Shareholding
16th Jan 20257:06 amRNSOptima Health to acquire BHSF Occupational Health
27th Dec 20241:35 pmRNSDirector / PDMR Shareholding
20th Dec 20244:24 pmRNSHolding(s) in Company
19th Dec 20244:35 pmRNSDirector / PDMR Shareholding
19th Dec 20249:36 amRNSHolding(s) in Company
19th Dec 20247:00 amRNSDirector/PDMR Shareholding
11th Dec 20247:00 amRNSInterim results
10th Dec 20246:27 pmRNSHolding(s) in Company
27th Nov 20247:00 amRNSNotice of Results
29th Oct 20249:28 amRNSHolding(s) in Company
18th Oct 20247:00 amRNSDirector/PDMR Shareholding
16th Oct 20247:00 amRNSDirector/PDMR Shareholding
7th Oct 20244:33 pmRNSDirector/PDMR Shareholding
2nd Oct 20247:00 amRNSHolding(s) in Company
1st Oct 20244:10 pmRNSHolding(s) in Company
30th Sep 20242:08 pmRNSHolding(s) in Company
30th Sep 202410:21 amRNSHolding(s) in Company
30th Sep 20247:34 amRNSDirector/PDMR Shareholding
26th Sep 20247:00 amRNSFirst Day of Dealings on AIM
11th Jan 20117:00 amRNSOPT achieves Lloyd's Register certification
20th Dec 20107:00 amRNSDirector's Dealing
10th Dec 20107:00 amRNSOPT Q2 Results
2nd Dec 20107:00 amRNSCancellation of trading on AIM
1st Dec 20107:00 amRNSNotice of Results
8th Nov 20107:00 amRNSOPT expands relationship with Mitsui in Japan
15th Oct 20102:54 pmRNSDirector's Dealing
13th Oct 20101:36 pmRNSDirector's Dealing
11th Oct 20104:31 pmRNSGrant and additional listing of shares
8th Oct 201012:18 pmRNSDirector's Dealing
8th Oct 201012:15 pmRNSResult of AGM
6th Oct 20106:00 pmRNSDirector's Dealing
4th Oct 20107:00 amRNSOPT awarded $2.75m by US Navy
27th Sep 20101:30 pmRNSOPT completes first ever USA grid connection

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.